ArticleAntiviral research2010
Antiviral prevention of sepsis induced cytomegalovirus reactivation in immunocompetent mice.
Article in Antiviral research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 29 citations in OpenAlex.
- Safety and Efficacy of Antiviral Therapy for Prevention of Cytomegalovirus Reactivation in Immunocompetent Critically Ill Patients: A Randomized Clinical Trial.JAMA internal medicine · 2017Trial
- Review
- Current Understanding of Cytomegalovirus Reactivation in Critical Illness.The Journal of infectious diseases · 2020Review
- Role of antibodies in confining cytomegalovirus after reactivation from latency: three decades' résumé.Medical microbiology and immunology · 2019Review
- Cytomegalovirus reactivation in a critically ill patient: a case report.Journal of medical case reports · 2018Article
- Impaired polyfunctionality of CD8Experimental & molecular medicine · 2017Article
- Antiviral prophylaxis of cytomegalovirus reactivation in immune competent patients-the jury remains out.Journal of thoracic disease · 2017Article
- Broncholaveolar lavage to detect cytomegalovirus infection, latency, and reactivation in immune competent hosts.Journal of medical virology · 2016Article
- Sepsis and cytomegalovirus: foes or conspirators?Medical microbiology and immunology · 2015Review
- Resistant pathogens, fungi, and viruses.The Surgical clinics of North America · 2014Review
- STAT3-mediated IL-17 production by postseptic T cells exacerbates viral immunopathology of the lung.Shock (Augusta, Ga.) · 2012Article
- Cytomegalovirus reactivation in critically ill immunocompetent hosts: a decade of progress and remaining challenges.Antiviral research · 2011Review
- [Ventilator-associated viral pneumonia].Reanimation : journal de la Societe de reanimation de langue francaise · 2011Article
- CMV in critically ill patients: pathogen or bystander?Reviews in medical virology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
introductionImmunocompetent patients can reactivate latent cytomegalovirus (CMV) during critical illness and reactivation is associated with significantly worse outcomes. Prior to clinical trials in humans to prove causality, we sought to determine an optimal antiviral treatment strategy.
methodsMice latently infected with murine CMV (MCMV) received a septic reactivation trigger and were randomized to receive one of four ganciclovir regimens or saline. Lungs were evaluated for viral transcriptional reactivation and fibrosis after each regimen. Influences of ganciclovir on early sepsis-induced pulmonary inflammation and T-cell activation were studied after sepsis induction.
resultsAll ganciclovir regimens reduced measurable MCMV transcriptional reactivation, and 10mg/day for 7 or 21 days was most effective. Lower dose (5mg/kg/day) or delayed therapy was associated with significant breakthrough reactivation. Higher doses of ganciclovir given early were associated with the lowest incidence of pulmonary fibrosis, and delay of therapy for 1 week was associated with significantly worse pulmonary fibrosis. Although bacterial sepsis induced activation of MCMV-specific pulmonary T-cells, this activation was not influenced by ganciclovir.
conclusionThese results suggest that antiviral treatment trials in humans should use 10mg/kg/day ganciclovir administered as early as possible in at-risk patients to minimize reactivation events and associated pulmonary injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.